dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Patient Education

Patient Education

  • There is no clear evidence of specific association between lifestyle factors and dyspepsia, but some individuals may be helped by these measures
  • To reduce anxiety in cases where there are no indications of organic disease, reassurance is an important part of initial therapy
  • Provide patients with access to educational materials to support the care they receive and emphasize adherence to medical therapy

Lifestyle Modification

  • Advise patients to avoid known precipitants that they associate with dyspeptic symptoms eg alcohol, coffee, chocolate and fatty foods
    • Alcohol, coffee, and chocolate have pharmacological effects that may reduce the tone of the lower esophageal sphincter (LES)
    • Fatty foods delay gastric emptying time which may also predispose to GERD
  • Encourage patient to stop smoking
    • Smoking has pharmacological effects that may reduce the tone of the LES
  • Weight reduction for overweight and obese patients
    • Obesity may disrupt the LES due to mechanical pressure on the diaphragm
  • May suggest having a main meal well before going to bed (preferably 3 hours before)
  • Some patients may benefit from raising the head when sleeping
    • Lying flat may increase reflux episodes since gravity does not prevent acid regurgitation

Other Considerations

  • If there is concurrent use of NSAIDs, evaluate for risk of GI complications and consider alternative strategies if risk is a concern, eg use of enteric-coated NSAIDs 
    • See Peptic Ulcer Disease Disease Management Chart for details
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 5 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.